Anti-GABAA Receptor ß3 Antibody

Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system, causing a hyperpolarization of the membrane through the opening of a Cl− channel associated with the GABA-A receptor (GABA-A-R) subtype. GABA-A-Rs are important therapeutic targets for a range of sedative, anxiolytic, and hypnotic agents and are implicated in several diseases including epilepsy, anxiety, depression, and substance abuse. The GABA-A-R is a multimeric subunit complex. To date six αs, four βs and four γs, plus alternative splicing variants of some of these subunits, have been identified (Olsen and Tobin, 1990; Whiting et al., 1999; Ogris et al., 2004) . Injection in oocytes or mammalian cell lines of cRNA coding for α- and β-subunits results in the expression of functional GABA-A-Rs sensitive to GABA. However, coexpression of a γ-subunit is required for benzodiazepine modulation. The various effects of the benzodiazepines in brain may also be mediated via different α- subunits of the receptor (McKernan et al., 2000; Mehta and Ticku, 1998; Ogris et al., 2004; Pöltl et al., 2003) .

ECA5 antibody, GABA alpha receptor beta-2 subunit antibody, GABA (A) receptor subunit beta-3 antibody, GABAA receptor beta 3 subunit antibody, GABAA receptor subunit beta 3 antibody, GABR B3 antibody, Gabrb3 antibody, Gamma aminobutyric acid (GABA) A receptor beta 3 antibody, Gamma aminobutyric acid receptor subunit beta 3 antibody, Gamma-aminobutyric acid receptor subunit beta-3 antibody, GBRB3_HUMAN antibody, MGC9051 antibody

For research use only. Not intended for therapeutic or diagnostic use. Use of all products is subject to our terms and conditions, which can be viewed on our website.